Ninety-four patients underwent high-dose chemotherapy with stem cell support for stage IV breast cancer. The high-dose chemotherapy consisted of the Stamp V regimen in all patients comprising cyclophosphamide, thiotepa and carboplatin (CTCb). Twenty-three patients received sequential high-dose therapies with the first consisting of high-dose melphalan and the second of Stamp V. Two patients died from chemotherapy-related complications resulting in a transplant-related mortality at 100 days of 2.2%. The progression-free survival at 3 years was 36% in patients with no evidence of disease at the first course of high-dose therapy compared with 17% in patients with remaining disease at time of the high-dose therapy (P = 0.03). There was no difference in overall survival between patients with no evidence of disease and other patients. The source of stem cells, single or double courses of high-dose therapy, positive selection of CD34 + cells, or number of involved sites had no influence on either progression-free survival or overall survival. Further studies of more intensive induction chemotherapy followed by high-dose therapy with stem cell support are indicated.
High-dose chemotherapy with stem cell support is increasingly used for therapy of women with breast cancer stage IV. [1] [2] [3] [4] [5] One randomized study was published showing superior outcome for patients receiving primary high-dose therapy with stem cell support compared with conventionaldose chemotherapy. 6 Patients who are refractory to standard-dose chemotherapy respond poorly to high-dose therapy and patients who do respond have a high relapse risk. In uncontrolled pilot and phase II studies, patients with chemosensitive disease seem to do better, with progressionfree survival at 3-5 years after high-dose therapy of 15-20%. [1] [2] [3] [4] Peripheral blood stem cells are today almost
Correspondence: Dr P Ljungman, Dept. of Hematology, Huddinge University Hospital, SE-14186 Huddinge, Sweden Received 1 December 1997; accepted 9 April 1998 exclusively used for support after high-dose therapy, which has shortened the neutropenic period and reduced the treatment-related morbidity and mortality. The purpose of this report was to analyze outcome in a consecutive series of patients treated with high-dose therapy.
Patients and methods

Patients
Ninety-four patients who underwent high-dose chemotherapy with autologous stem cell support for chemotherapy responsive stage IV breast cancer between 1 January 1991 and 1 December 1996 at one of four participating hospitals were eligible for the study. Patient characteristics are shown in Table 1 . Tumor evalutation after standard chemotherapy was performed by conventional clinical examination combined with relevant radiographic procedures.
Transplant procedure
The patients could be included in either a single (n = 71) or a double high-dose (n = 23) therapy protocol. If a single transplant protocol was used, the high-dose chemotherapy consisted of the combination of cyclosphosphamide 2 ). One patient received the CTCb combined with paclitaxel due to a complete response on single agent paclitaxel therapy as second-line therapy. If a double transplant protocol was used, the first high-dose chemotherapy consisted of melphalan 140-180 mg/m 2 followed as soon as possible by the cyclosphosphamide, thiotepa and carboplatin combination as the second high-dose regimen.
Graft composition
The stem cell support consisted of bone marrow (n = 9), peripheral blood stem cells (n = 78) or a combination of both (n = 7). Peripheral blood stem cells were mobilized with combination chemotherapy followed by G-CSF in 69 patients, cyclophosphamide followed by G-CSF in three patients, and GM-CSF alone in two patients. The combination chemotherapy consisted of FEC (5-fluorouracil, epirubicin and cyclophosphamide) in 55 patients, FAC (5-fluorouracil, doxorubicin and cyclophosphamide) in four patients, and epirubicin and paclitaxel in three patients. Collection of a minimum of 2.0 × 10 6 CD34 + cells/kg was required for a single course high-dose therapy and approximately 4.0 × 10 6 CD34 + cells/kg for double courses of highdose therapy. Seven patients were included in an experimental protocol with CD34
+ positive selection with the Ceprate column (Cellpro, Bothell, WA, USA).
Supportive care
Supportive care was given according to the regimen of each center. Most patients received antimicrobial prophylaxis with ciprofloxacin and acyclovir. Fluconazole was given according to each center's regimen. G-CSF was given after stem cell infusion also according to the regimens of each center. Most patients received prophylaxis against emesis with 5-HT3 blocking drugs. Combination of 5-HT3 blocking drugs with corticosteroids was avoided.
Statistics
Survival and PFS were calculated by the Kaplan-Meier product limit method. Effect of different factors on outcome were analyzed by the log-rank test. A Cox proportional hazards model was constructed to analyze potential prognostic factor effects on progression-free survival (PFS).
Results
Transplant-related mortality
Two patients died from transplant-related complications. One patient died of congestive heart failure and the second patient died due to a central venous catheter-related C. albicans fungemia after the second high-dose therapy. The therapy-related mortality at 100 days was 2.2%.
Overall survival
The estimated overall survival at 3 years for all patients was 50%. There was no difference in overall survival between patients who had no evidence of disease (NED) at the time of first high-dose therapy compared with patients who were in PR at the first high-dose therapy (Figure 1) . Furthermore, there was no difference in survival between patients who received single or double courses of high-dose therapy in either patients who had NED or in patients with measurable disease at the first course of high-dose therapy. The estimated 3 year survival in patients with NED was 51% for patients who received single and 66% for patients receiving double high-dose therapy. The corresponding 3 year survival was 49% for patients in PR who received single and 35% for patients who received double courses of high-dose therapy. Finally, there was no difference in survival between patients who received CD34
+ selected stem cells and those who did not (3 year survival 40% and 50%, respectively).
Progression-free survival
The estimated PFS at 3 years for all patients was 27%. Patients with NED had a significantly better PFS than patients with evidence of disease at the time of the first course of high-dose therapy (P = 0.03; Figure 2 ). The number of involved sites did not influence outcome. Patients with liver metastases did worse than other patients (median PFS 8 months and 13 months, respectively; P = 0.07) while patients with pulmonary disease had the same outcome as other patients (median survival 13 months and 13 months, respectively). Furthermore, there was no difference in estimated 3 year PFS between patients who received single or double courses of high-dose therapy in either patients with NED or in those with measurable disease at the first course of high-dose therapy (data not shown). However, the number of patients receiving double courses of high-dose therapy in each group was small. Different graft compositions were used in the study. There was no difference in PFS between patients who received bone marrow cells, peripheral blood stem cells or the combination of bone marrow and peripheral blood stem cells. Furthermore, there was no difference between unselected and CD34 + selected stem cells (data not shown). In a Cox proportional hazards model including status of disease at high-dose therapy (NED vs measurable disease), number of high-dose courses, graft composition, or CD34-positive selection, only status of disease had a significant influence on PFS (P = 0.04).
Discussion
Therapy of metastatic breast cancer is a complicated issue. However, a dose-response relationship in the conventionaldose range has been demonstrated beyond reasonable doubt. 7 Despite this relationship the majority of studies have failed to demonstrate a survival benefit for higher doses in the conventional-dose range. 7 High-dose therapy with stem cell support utilizes the dose-response concept in breast cancer. 2, 5, 7, 8 To date, the available data were mainly obtained via pilot and phase II studies. Recently, a relatively small phase III study also demonstrated a statistically significant survival benefit for patients receiving high-dose therapy supported by marrow cells compared with conventional-dose chemotherapy given for six to eight courses. 6 However, the majority of other pilot and phase I-II studies have chosen to offer high-dose therapy to patients responding to conventional-dose therapy.
This report describes a series of 94 consecutive patients receiving high-dose therapy for metastatic breast cancer at four Swedish transplant centers. All patients received the Stamp V regimen with cyclophosphamide, thiotepa and carboplatin developed by K Antman.
2 During the 5-year period autologous bone marrow cells were replaced by mobilized peripheral blood stem cells. In most patients the mobilization chemotherapy consisted of FEC with a slightly increased cyclophosphamide dose to 1200 mg/m 2 followed by G-CSF started on day 4 post therapy. This regimen resulted in a very predictive CD34 + cell peak in peripheral blood allowing precisely scheduled harvest procedures. 9 Transplant-related mortality in large registry reports has decreased over the last 5 years, associated in time with a change from bone marrow to peripheral blood stem cells. In our series the transplant-related mortality was 2.2% and only one of 85 patients receiving blood stem cells died from infection. Thus, the main factor determining long-term survival is freedom from progression of breast cancer. Several developments have been suggested as reducing the risk for disease progression after high-dose therapy. Increased intensity of chemotherapy given as induction therapy might improve outcome. Ayash et al 1 analyzed prognostic factors for long-term PFS and found that patients who achieve CR with initial chemotherapy had a favorable outcome. This is verified in our study since patients who were transplanted with NED had significantly improved PFS compared with other patients.
The high-dose therapy regimen might be improved. New regimens incorporating paclitaxel or doxorubicin have been studied in dose-escalating trials. 10, 11 However, until now no regimen has been shown to be superior to the Stamp V regimen although no randomized trial has been performed. Another potential method of improving the high-dose regimen is to give tandem courses of high-dose therapy. This strategy was studied in a phase II trial and the initial results were encouraging. 12 However, in an updated series with more patients and longer follow-up the same group failed to see an improved PFS after tandem courses of therapy. Bitran et al 13 found a favorable outcome after tandem highdose therapy by administering a high-dose regimen consisting of thiotepa and cyclophosphamide followed by a second high-dose course with high-dose melphalan. The 2 year PFS in the study by Bitran et al was 56%. In our study, we found no improvement of either PFS or survival in patients receiving double courses of high-dose therapy after a similar treatment schedule as used by Ayash et al. Thus, if tandem high courses of therapy are used, more effective regimens are needed, for example, with the addition of paclitaxel.
A third possibility for improving long-term PFS might be to reduce contamination of the stem cell graft by purging either by positive selection of CD34 + cells or by removing tumor cells with magnetic beads, or a combination of both methods. It was shown by Brugger et al 14 that mobilization chemotherapy also mobilizes tumor cells into the peripheral blood. Shpall et al 15, 16 have shown that positive selection of CD34
+ cells can reduce the number of breast cancer cells in bone marrow or peripheral blood stem cell grafts. However, it is unknown whether tumor cells contribute to progression of breast cancer after high-dose therapy with stem cell support. Our series included only seven patients who had grafts positively selected for CD34
+ cells and therefore we cannot draw any conclusion regarding the efficacy of stem cell selection.
Thus, in this series the most important factor for PFS seemed to be disease status at high-dose therapy, which was verified in a Cox proportional hazards model including the different treatment variants (single vs double grafts; graft composition; CD34 + positive selection or not). Ideally the concept of high-dose therapy with stem cell support should be tested in a prospective and controlled phase III trial as was initiated by the breast cancer therapy group in Stockholm in 1991. Unfortunately, in this study comparing high-dose therapy supported by bone marrow cells with conventional therapy in responding patients we were only able to include nine patients. All five patients in the conventional arm relapsed within 14 months while two of four patients in the high-dose arm are still progression free. 17 The study by Bezwoda et al 6 and registry data from the United States and Europe will make it even more difficult to randomize patients between these two options. There are other randomized trials ongoing that have problems with patient inclusion. The present study on a consecutive series of patients should be seen in this context. The 5-year survival for patients with metastatic disease responding to conventional-dose chemotherapy is in the order of 10-20% while the present series discloses a calculated 5-year survival in the order of 30-40%. This background supports the need for a controlled study but the choice of therapies must be acceptable for patients and oncologists. Thus, we believe that further studies of more intensive induction chemotherapy followed by high-dose therapy with stem cell support are indicated.
